Find Industry reports, Company profilesReportLinker                                                                       ...
Find Industry reports, Company profilesReportLinker                                                                       ...
Find Industry reports, Company profilesReportLinker                                                                       ...
Find Industry reports, Company profilesReportLinker                                                                       ...
Find Industry reports, Company profilesReportLinker                                                                       ...
Upcoming SlideShare
Loading in...5
×

Generic and innovative drugs market in Poland 2012

87

Published on

Generic and innovative drugs market in Poland 2012- Development forecasts for 2012-2014Generic and innovative drugs market in Poland 2012, Development forecasts for 2012-2014 is a comprehensive source of data and analysis focused on recent and impending changes in the market resulting from the January 2012 reimbursement act. This legislation has the power to change the framework of the Polish pharmaceutical sector, particularly the generic and innovative drug segments, and the report guides readers to a thorough understanding of the act's provisions and offers ways for companies to adapt to the new rules and preserve their profits.In addition to providing complete forecasts for these two segments, as well as for the overall pharmaceutical industry in Poland to 2014, this document supplies data on the market share occupied by these two drug categories in terms of value and volume, and prices of innovative drugs and generics in Poland and as compared to other markets. It simplifies complex issues such as the Polish reimbursement process, upcoming changes to reimbursement and the lists of reimbursed and non-reimbursed drugs, fixed outlays of the National Health fund, payment structures and operations of therapies vs. medications.Topics essential to manufacturers and producers of generic and innovative drugs include: evaluation of the effects of the new act on major market players, suggested methods of limiting potentially harmful effects to businesses, changes in prices of top products in these categories, changes to reimbursements and refund status, role of the AOTM and other agencies in the reimbursement decision process, recent price negotiations with government agencies, funding limits and fixed prices and margins. Generic and innovative drugs market in Poland 2012, Development forecasts for 2012-2014 contains vital data on the current market, explanation of all changes due to new regulation and projects for the future of this important part of the pharmaceutical industry.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
87
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Generic and innovative drugs market in Poland 2012

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Generic and innovative drugs market in Poland 2012Published on May 2012 Report SummaryGeneric and innovative drugs market in Poland 2012- Development forecasts for 2012-2014Generic and innovative drugs market in Poland 2012, Development forecasts for 2012-2014 is a comprehensive source of data andanalysis focused on recent and impending changes in the market resulting from the January 2012 reimbursement act. This legislationhas the power to change the framework of the Polish pharmaceutical sector, particularly the generic and innovative drug segments,and the report guides readers to a thorough understanding of the acts provisions and offers ways for companies to adapt to the newrules and preserve their profits.In addition to providing complete forecasts for these two segments, as well as for the overall pharmaceutical industry in Poland to2014, this document supplies data on the market share occupied by these two drug categories in terms of value and volume, andprices of innovative drugs and generics in Poland and as compared to other markets. It simplifies complex issues such as the Polishreimbursement process, upcoming changes to reimbursement and the lists of reimbursed and non-reimbursed drugs, fixed outlays ofthe National Health fund, payment structures and operations of therapies vs. medications.Topics essential to manufacturers and producers of generic and innovative drugs include: evaluation of the effects of the new act onmajor market players, suggested methods of limiting potentially harmful effects to businesses, changes in prices of top products inthese categories, changes to reimbursements and refund status, role of the AOTM and other agencies in the reimbursement decisionprocess, recent price negotiations with government agencies, funding limits and fixed prices and margins.Generic and innovative drugs market in Poland 2012, Development forecasts for 2012-2014 contains vital data on the current market,explanation of all changes due to new regulation and projects for the future of this important part of the pharmaceutical industry. Table of ContentGeneric and innovative drugs market in Poland 2012Development forecasts for 2012-20141. Report methodology 72. Executive summary 113. Overview of the generic and innovative drugs market in Poland 154. Main trends and events 155. Main past trends and events 156. Main anticipated trends and events 257. Share of pharmaceutical market 298. Overall market 299. Rx pharmacy market 3010. Market size and forecasts for 2012-2014 31Generic and innovative drugs market in Poland 2012 (From Slideshare) Page 1/5
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!11. Overall market 3112. Rx pharmacy market 3313. Counterfeit products 3414. Drug reimbursement in Poland 3715. Pricing policies 3716. VAT rate 3717. Non-reimbursed drugs on the pharmacy market 3818. Reimbursed drugs on the pharmacy market 3819. Pricing policies 3820. Prices compared to other countries 4021. Patient co-payment 4122. The value of sales of reimbursed drugs 4223. Margins 4324. Drugs on the hospital market 4425. Generic substitution 4426. Reimbursement policies 4627. Reimbursement system 4628. Open (pharmacy) reimbursement 4629. Therapeutic/drug programmes 4730. Chemotherapy 5031. Reimbursement process 5032. Reimbursement application 5233. The Economic Committee 5234. The AOTM 5335. Risk-sharing tools 5436. Market structure 5437. Regular prescriptions and prescriptions for drugs for chronic diseases 5438. Reimbursement spending from the states and the patients perspective 5539. Type of payment 5640. ATC categories 5741. Reimbursement spending 5842. Open reimbursement 5843. Therapeutic programmes 6144. Chemotherapy 6145. Hospital segment 6346. Funding 6347. Drug selection 6348. Drug procurement 6349. Distribution 6450. Off-label use 6451. Latest changes to reimbursement lists 6552. Inclusion of new drugs in reimbursement lists 6553. Latest changes to reimbursement lists 6754. Controversies 7055. Expected changes to reimbursement lists 7256. Reimbursement reform Reimbursement Act 7357. Major changes 7358. Fixed spending on reimbursement and the pay-back mechanism 74Generic and innovative drugs market in Poland 2012 (From Slideshare) Page 2/5
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!59. Joint-limit groups 7560. Assessment of the Reimbursement Acts effect on market players 7661. Reducing the negative impact of the Reimbursement Act 7862. Key market players 8163. Market share 8164. Whole market 8165. Rx pharmacy market 8366. Hospital market 8467. Innovation ranking 8568. Innovation projects Innovative Economy Operational Programme 8669. Profiles of selected key market players 8770. Innovative companies 8771. Generic companies 10572. List of graphs 12373. List of tables 12774. About PMR 12975. Contact PMR 130Generic and innovative drugs market in Poland 2012 (From Slideshare) Page 3/5
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Generic and innovative drugs market in Poland 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 2 660.00 Quantity: _____ 1-5 User License--USD 3 990.00 Quantity: _____ Corporate License--USD 5 320.00 Quantity: _____ Global Site--USD 6 650.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Generic and innovative drugs market in Poland 2012 (From Slideshare) Page 4/5
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Generic and innovative drugs market in Poland 2012 (From Slideshare) Page 5/5

×